A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs SAR 425899 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Acronyms Restore
- Sponsors Sanofi
- 04 Apr 2019 Status changed from not yet recruiting to discontinued.
- 01 Oct 2018 Planned End Date changed from 26 May 2021 to 25 Aug 2021.
- 01 Oct 2018 Planned primary completion date changed from 26 May 2021 to 25 Aug 2021.